Nuvation Bio Inc - Ordinary Shares - Class A
NUVB
Market Cap$1.02B
Close$
$0.30
91.1% downside
Current Fair Value
91.1% downsideOvervalued by 91.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.02 Billion |
|---|---|
| Enterprise Value | $981.67 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.11 |
| Beta | 1.35 |
| Outstanding Shares | 340,746,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.99 |
|---|---|
| PEG | 5.72 |
| Price to Sales | - |
| Price to Book Ratio | 3.42 |
| Enterprise Value to Revenue | 68.39 |
| Enterprise Value to EBIT | -4.56 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 0.57 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Nuvation Bio Inc
36 employeesNuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically ...